Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

63.86 +0.11 (+0.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again? ↗

January 09, 2022

The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market...

Via Benzinga

Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More ↗

December 10, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE:

Via Benzinga

BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo ↗

November 22, 2021

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals...

Via Benzinga

Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know ↗

November 16, 2021

Warren Buffet's Berkshire Hathaway added more than 13 million shares.

Via Investor's Business Daily

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Earnings Scheduled For May 11, 2021 ↗

May 11, 2021

Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 16, 2021

Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 16, 2021

Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday.

Via InvestorPlace

36 Stocks Moving in Tuesday's Pre-Market Session ↗

November 16, 2021

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss. Kezar Life Sciences, Inc. (NASDAQ:...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 15, 2021

Gainers Kezar Life Sciences (NASDAQ:KZR) s...

Via Benzinga

Royal Pharma (RPRX) Q3 2021 Earnings Call Transcript ↗

November 12, 2021

RPRX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021 ↗

October 29, 2021

Upgrades For Preferred Bank (NASDAQ:

Via Benzinga

AstraZeneca's Two Asthma Trials Meet Primary Endpoints ↗

September 09, 2021

Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of...

Via Benzinga

Cramer Gives His Opinion On Applied Materials, Coinbase And More ↗

August 26, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said Applied Materials, Inc. (NASDAQ: AMAT) reported an excellent quarter. People who were selling the stock didn...

Via Benzinga

Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma ↗

August 17, 2021

Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and...

Via Benzinga

Royal Pharma (RPRX) Q2 2021 Earnings Call Transcript ↗

August 11, 2021

RPRX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Royalty Pharma Q2 Earnings ↗

August 11, 2021

Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

Earnings Scheduled For August 11, 2021 ↗

August 11, 2021

Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is...

Via Benzinga

Why MorphoSys Stock Sank This Week ↗

June 03, 2021

Investors weren't happy about the drugmaker's wheeling and dealing.

Via The Motley Fool

Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover ↗

June 02, 2021

MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high.

Via Investor's Business Daily

Royalty Pharma Insights: Return On Capital Employed ↗

June 02, 2021

Royalty Pharma (NASDAQ:RPRX) posted a 26.99% decrease in earnings from Q4. Sales, however, increased by 0.18% over the previous quarter to $573.03 million. Despite the increase in...

Via Benzinga

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma ↗

June 02, 2021

MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of...

Via Benzinga

Repros Therapeutics (RPRX) Q1 2021 Earnings Call Transcript ↗

May 11, 2021

RPRX earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma? ↗

May 09, 2021

Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.

Via The Motley Fool

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

Insider Sells Royalty Pharma's Shares ↗

April 14, 2021

A Form 4 filing filed with the SEC on Wednesday, April 14 showed that EVP Reddoch James F. sold 359 shares of Royalty Pharma Inc (NASDAQ:RPRX) at an average price of $42.32...

Via Benzinga

Topics Regulatory Compliance

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront ↗

April 08, 2021

Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an...

Via Benzinga

Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

April 08, 2021

From Dicerna Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.